Staines, HM;
Kirwan, DE;
Clark, DJ;
Adams, ER;
Augustin, Y;
Byrne, RL;
Cocozza, M;
Cubas-Atienzar, AI;
Cuevas, LE;
Cusinato, M;
et al.
Staines, HM; Kirwan, DE; Clark, DJ; Adams, ER; Augustin, Y; Byrne, RL; Cocozza, M; Cubas-Atienzar, AI; Cuevas, LE; Cusinato, M; Davies, BMO; Davis, M; Davis, P; Duvoix, A; Eckersley, NM; Forton, D; Fraser, AJ; Garrod, G; Hadcocks, L; Hu, Q; Johnson, M; Kay, GA; Klekotko, K; Lewis, Z; Macallan, DC; Mensah-Kane, J; Menzies, S; Monahan, I; Moore, CM; Nebe-von-Caron, G; Owen, SI; Sainter, C; Sall, AA; Schouten, J; Williams, CT; Wilkins, J; Woolston, K; Fitchett, JRA; Krishna, S; Planche, T
(2021)
IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Emerg Infect Dis, 27 (1).
ISSN 1080-6059
https://doi.org/10.3201/eid2701.203074
SGUL Authors: Staines, Henry Michael Hu, Qinxue Krishna, Sanjeev Macallan, Derek Clive Planche, Timothy David Moore, Catherine Margaret Clark, David John Augustin, Yolanda Sydney Cusinato, Martina Elisa
|
PDF
Published Version
Available under License ["licenses_description_publisher" not defined]. Download (1MB) | Preview |
|
![]() |
Microsoft Excel (Appendix 2)
Published Version
Available under License ["licenses_description_publisher" not defined]. Download (31kB) |
Abstract
We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29–May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS-CoV-2 infection. We measured IgG against SARS-CoV-2 and compared antibody levels with patient outcomes, demographic information, and laboratory characteristics. We found that 2.0%–8.5% of persons did not seroconvert 3–6 weeks after infection. Persons who seroconverted were older, were more likely to have concurrent conditions, and had higher levels of inflammatory markers. Non-White persons had higher antibody concentrations than those who identified as White; these concentrations did not decline during follow-up. Serologic assay results correlated with disease outcome, race, and other risk factors for severe SARS-CoV-2 infection. Serologic assays can be used in surveillance to clarify the duration and protective nature of humoral responses to SARS-CoV-2 infection.
Statistics
Actions (login required)
![]() |
Edit Item |